TrialClinical lung cancer2023

Short Report of a Phase II Trial of Nintedanib in Recurrent Malignant Pleural Mesothelioma (MPM).

Antoinette J Wozniak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.